Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

How Superbugs Control Their Lethal Weapons
It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone"s advantage.

Screening Of First-Degree Relatives Of Patients With Bicuspid Aortic Valve Recommended
Bicuspid Aortic Valve (BAV), a condition in which patients" aortic valves have just two leaflets instead of the normal three, is the most common cardiac anomaly, affecting up to two percent of the general population. The defect can result in calcification deposits on the heart valve, leakage of the valve and may results in a feeling of tightness in the chest as well as shortness of breath. The condition is easily diagnosed; often physicians can hear a "click" or a murmur when they listen to a BAV patient"s heart with a stethoscope.
News of the day
Second U.S. Independent Laboratory Confirms That Oculus Innovative Sciences' Microcyn(R) Technology Effective At Inactivating H1N1 Swine Flu
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which includes new formulations intended to reduce the use of antibiotics by preventing or treating infections including those caused by bacteria and viruses, has confirmed the effectiveness of Microcyn® Technology at inactivating the H1NI Swine Influenza A. In a virucidal time-kill suspension test conducted by an independent laboratory, BioScience Laboratories, Inc., the specific Microcyn Technology formulation reduced infectivity of the swine flu virus by 4.00log10 (99.99%) reduction after just 30-seconds exposure. BioScience Laboratories, working in cooperation with the U.S. Department of Agriculture, received formal approval to acquire, house and evaluate the specific swine influenza virus in April 2009.
Endocrinology

The American Society Of Hematology Announces New Honorific Award

The American Society of Hematology (ASH) announces the debut of the Ernest Beutler Lecture and Prize, to be awarded at ASH"s annual meeting in December. The inaugural recipients are Thomas Maniatis, PhD, of Harvard University, and Yuet Wai Kan, MD, of the University of California - San Francisco. Established in December 2008, this award, named for the late Dr. Ernest Beutler, past president of ASH and physician-scientist for over 50 years, is a two-part lectureship intended to recognize major translational advances related to a single topic. This award honors two individuals, one who has enabled advances in basic science and another individual for achievements in clinical science or translational research. Both of this year"s recipients have made seminal contributions to our understanding of the biology and diagnosis of thalassemia, with specific attention paid to the impact of molecular genetic studies of globin genes on the diagnosis and treatment of the disease. Dr. Kan, past ASH President and prior recipient of the Dameshek Prize and Stratton Medal for his pioneering work involving the use of fetal DNA to diagnose sickle cell anemia and thalassemia, will discuss the development of prenatal and DNA diagnosis for thalassemia, reviewing current and experimental treatments, and the impact of stem cell technology on future therapy. Dr. Maniatis, of Harvard University, will discuss the development of prenatal and DNA diagnosis for thalassemia, reviewing current and experimental treatments and the impact of stem cell technology on future therapy. The Ernest Beutler Lecture will take place on Monday, December 7th from 12:30 to 1:30 p.m. in New Orleans, LA. For more information, please visit the 51st ASH Annual Meeting Web site. The American Society of Hematology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009